SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-006498
Filing Date
2020-05-13
Accepted
2020-05-13 16:25:20
Documents
67
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akro-20200331x10q.htm 10-Q 1697330
2 EX-31.1 akro-20200331ex311e96bb7.htm EX-31.1 11725
3 EX-31.2 akro-20200331ex312fe0e15.htm EX-31.2 12658
4 EX-32.1 akro-20200331ex321758a13.htm EX-32.1 11349
  Complete submission text file 0001558370-20-006498.txt   5914972

Data Files

Seq Description Document Type Size
5 EX-101.INS akro-20200331.xml EX-101.INS 1209196
6 EX-101.SCH akro-20200331.xsd EX-101.SCH 42227
7 EX-101.CAL akro-20200331_cal.xml EX-101.CAL 36412
8 EX-101.DEF akro-20200331_def.xml EX-101.DEF 118877
9 EX-101.LAB akro-20200331_lab.xml EX-101.LAB 406014
10 EX-101.PRE akro-20200331_pre.xml EX-101.PRE 295907
Mailing Address 170 HARBOR WAY SOUTH SAN FRANCISCO CA 94080
Business Address 170 HARBOR WAY SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38944 | Film No.: 20873513
SIC: 2834 Pharmaceutical Preparations